Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aquestive Therapeutics ( (AQST) ) has shared an announcement.
Aquestive Therapeutics reported its third quarter 2025 financial results and provided a business update, highlighting preparations for the potential U.S. launch of Anaphylm, a needle-free oral medication for severe allergic reactions, pending FDA approval in early 2026. The company also advanced its regulatory activities for Anaphylm in Canada and the EU, expanded its patent estate, and continued developing its product pipeline, including a topical gel for alopecia areata. Financially, the company saw a 4% year-over-year revenue increase excluding deferred revenue impacts, despite a net loss of $15.4 million due to higher commercial and regulatory expenses.
The most recent analyst rating on (AQST) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
Aquestive Therapeutics’ overall stock score is primarily impacted by its financial performance, which poses significant risks due to declining revenues and high leverage. While technical analysis shows strong bullish momentum, the valuation remains challenged by ongoing losses. The earnings call provided some positive developments, but financial and market access challenges persist.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines to improve patients’ lives through innovative science and delivery technologies. The company specializes in developing non-invasive therapies, such as sublingual films and topical gels, targeting various medical conditions including severe allergic reactions and alopecia areata.
Average Trading Volume: 2,976,325
Technical Sentiment Signal: Buy
Current Market Cap: $735.5M
Learn more about AQST stock on TipRanks’ Stock Analysis page.